ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid Tumors (NCT03686124)
Phase 1/2 Study Evaluating Genetically Modified Autologous T Cells Expressing a TCR Recognizing a Cancer/Germline Antigen as Monotherapy or in Combination With Nivolumab in Patients With Recurrent and/or Refractory Solid Tumors
🩺 Plain-English Summary (8th-Grade Level)
The study's purpose is to establish the safety and tolerability of IMA203/IMA203CD8 products with or without combination with nivolumab in patients with solid tumors that express preferentially expressed antigen in melanoma (PRAME).
Who can join: Review the eligibility criteria below.
Location: Stanford Cancer Institute — Stanford, California
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (21 Sites)
- Stanford Cancer Institute — Stanford, California
- University of Colorado, Anschutz Medical Campus — Aurora, Colorado
- University of Miami Hospital and Clinics — Miami, Florida
- University of Chicago Medical Center — Chicago, Illinois
- Massachusetts General Hospital — Boston, Massachusetts
- Memorial Sloan Kettering Cancer Center — New York, New York
- Ohio State University Wexner Medical Center Gynecologic Oncology at Mill Run — Columbus, Ohio
- University of Pennsylvania, Perelamn Center for Advanced Medicine — Philadelphia, Pennsylvania
- Thomas Jefferson University, Honickman Center — Philadelphia, Pennsylvania
- Fox Chase Cancer Center — Philadelphia, Pennsylvania
- University of Pittsburgh Medical Center — Pittsburgh, Pennsylvania
- University of Texas MD Anderson Cancer Center — Houston, Texas
- Fred Hutchinson Cancer Center — Seattle, Washington
- Universitätsklinikum Heidelberg, Nationales Centrum für Tumorerkrankungen (NCT) — Heidelberg, Baden-Wurttemberg
- Klinikum rechts der Isar der Technischen Universität München — Munich, Bavaria
- Universitätsklinikum Würzburg — Würzburg, Bavaria
- Universitätsklinikum Bonn - Medizinische Klinik III — Bonn, North Rhine-Westphalia
- Universitätsmedizin der Johannes Gutenberg-Universität Mainz — Mainz, Rhineland-Palatinate
- Universitätsklinikum C.-G.-Carus Dresden — Dresden, Saxony
- Charité Benjamin Franklin - Klinik für Hämatologie und Onkologie — Berlin,
- Universitätsklinikum Hamburg-Eppendorf — Hamburg,
📞 Contact the Study Coordinator
Phone: (346) 204-5400
Email: ctgovinquiries@immatics.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Refractory Cancer
- A Study of Avutometinib for People With Solid Tumor Cancers — Atlanta, Georgia
Explore by condition: All Refractory Cancer clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.